Home  |  Contact
Due to maintenance work, this service and ftp://ftp.expasy.org will be unavailable from Tuesday August 23rd 18:00 until Wednesday August 24th 08:00 CEST. Apologies for the inconvenience.

UniProtKB/Swiss-Prot P13866: Variant p.Phe405Ser

Sodium/glucose cotransporter 1
Gene: SLC5A1
Variant information

Variant position:  405
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Phenylalanine (F) to Serine (S) at position 405 (F405S, p.Phe405Ser).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from large size and aromatic (F) to small size and polar (S)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In GGM; loss of activity.
Any additional useful information about the variant.



Sequence information

Variant position:  405
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  664
The length of the canonical sequence.

Location on the sequence:   VMLASLMSSLTSIFNSASTL  F TMDIYAKVRKRASEKELMIA
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         VMLASLMSSLTSIFNSASTLFTMDIYAKVRKRASEKELMIA

Mouse                         VMMASLMSSLTSIFNSASTLFTMDIYTKIRKKASEKELMIA

Rat                           VMMASLMSSLTSIFNSASTLFTMDIYTKIRKGASEKELMIA

Rabbit                        VMMASLMSSLTSIFNSASTLFTMDIYTKIRKKASEKELMIA

Sheep                         VMLASLMSSLTSIFNSASTLFTMDIYTKIRKKASEKELMIA

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 664 Sodium/glucose cotransporter 1
Topological domain 402 – 423 Cytoplasmic
Disulfide bond 255 – 511
Mutagenesis 396 – 396 S -> A. Loss of activity.


Literature citations

Defects in Na+/glucose cotransporter (SGLT1) trafficking and function cause glucose-galactose malabsorption.
Martin M.G.; Turk E.; Lostao M.P.; Kerner C.; Wright E.M.;
Nat. Genet. 12:216-220(1996)
Cited for: VARIANTS GGM ASN-28; GLY-28; SER-51; TRP-135; PRO-159; THR-166; 191-TYR--ALA-664 DEL; 254-LYS--ALA-664 DEL; LEU-276; TYR-292; ARG-295; SER-300; VAL-304; SER-369; 379-ARG--ALA-664 DEL; GLN-379; VAL-388; SER-405; THR-411; ARG-426; ASN-470; HIS-499 AND GLN-615; FUNCTION; TRANSPORTER ACTIVITY;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.